Michael Beaubaire, MD
Chief Executive Officer
Dr. Michael Beaubaire is an established life sciences executive with extensive experience in early stage drug development and how it relates to the regulatory world and commercial markets, as well as financial expertise in capital markets and venture capital.
Dr. Beaubaire most recently serves as the Chair of the Scientific Advisory board of Lincoln Park Capital LLC, a fundamental equity investor in life sciences, where he is responsible for assessing clinical and scientific opportunities in micro-cap and private life science organizations, as well as evaluating reviewing and overseeing investment opportunities. Over the course of his career, he has played significant roles advising emerging life science and device companies, healthcare service organizations, and interested institutional healthcare investors through his own advisory firm and affiliating with leading investment banks and strategic management consulting firms.
Dr. Beaubaire earned his BS with Honors in Finance from the Wharton School, and his BA with Honors in Biological Basis of Behavior from the College of Arts & Sciences, both at the University of Pennsylvania. He received his Medical Doctorate degree from Northwestern University Medical School, and trained as an Internal Medicine resident at Evanston Northwestern Healthcare where he served as an educator to medical interns and students under his tutelage.
Robert Bender has been active in entrepreneurial, technology-based companies, primarily in life sciences and health care. His professional focus has been on the assessment and development of new ventures. He has extensive experience in institutional and private venture capital, and has participated in the management and development of a number of companies, including Sunopta, ens BIO LOGICALS, Neurochem, Theseus Medical Imaging, Immune Control Inc., Atreus Pharma, MSK Metrics, Revivo Therpaeutics Inc., ERAD Tx., and Zephyrious Health Inc. He currently serves as Chairman of two companies with clinical development programs and maintains an active consultancy in strategic development and marketing for technology companies. During his career he has ‘worked both sides’ of company funding and has experience in both institutional venture capital and investment banking for private and public company transactions.
Mr. Bender’s background training was in chemistry and molecular biology; translation of academic research thru the development of processes and products has been a central theme of his activities and he has enjoyed hands-on roles in a diverse range of companies spanning a wide range of operating technologies and scales. Cross disciplinary innovation and building functional teams to solve complex problems has been both intellectually and financially rewarding. He has several publications in both the scientific and patent literature and continues to be interested in the development of new technologies and products.
Allan M. Green, MD, PhD, JD.
Dr. Allan Green is a physician, attorney, and research scientist who has significant operating management experience with a number of successful biomedical companies. Dr. Green holds several US Patents, has served as a technical consultant to a variety of government committees. He has held several medical school appointments and is the author of numerous peer-reviewed scientific papers on biochemistry and drug development.
Dr. Green is well known for his Issues and Commentary series that analyzes competitive commercial aspects and potential markets for emerging pharmaceutical technologies. He has successfully represented many American and non-U.S. clients in their relationships with the FDA and has organized a number of multi-disciplinary conferences on healthcare, pharmaceutical and funding issues. He was formerly Medical Director of New England Nuclear Corporation, a Founder of Neurochem, Inc., and Of Counsel to the law firm of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Dr. Green is Adjunct Professor of Law at Boston College Law School where he teaches Food and Drug Law.
Dr. Allan Green and Robert Bender founded Atreus Pharma, a company which developed annexin V as an imaging agent; Atreus Pharma was purchased by Advanced Accelerator Applications and the imaging program started by Atreus is currently in Phase 3 trials.